Loading...
XNAS
TCRT
Market cap5mUSD
Jul 09, Last price  
2.07USD
1D
0.00%
1Q
-28.37%
Jan 2017
-99.74%
IPO
-99.66%
Name

Alaunos Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:TCRT chart
P/E
—
P/S
1,011.05
EPS
—
Div Yield, %
—
Shrs. gr., 5y
6.87%
Rev. gr., 5y
-49.08%
Revenues
5k
-50.00%
00000667,000800,000800,0001,373,0004,332,0006,861,0006,389,000146,00000398,0002,922,0005,00010,0005,000
Net income
-4m
L-10.75%
-17,856,919-26,608,246-25,231,000-7,649,000-32,670,000-63,778,000-96,132,000-57,107,000-31,781,000-120,088,000-165,297,000-54,323,000-53,117,000-117,796,000-79,976,000-78,751,000-37,730,000-35,140,000-4,679,000-4,176,000
CFO
-3m
L-42.29%
-14,421,115-21,650,205-23,519,000-12,294,000-19,694,000-38,835,000-78,832,000-59,509,000-36,650,000-10,000-58,325,000-54,669,000-49,457,000-40,854,000-57,013,000-61,468,000-29,232,000-30,142,000-4,971,000-2,869,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials, which comprises ten T-cell receptors designed to target mutated KRAS, TP53, and EGFR in various cancers such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. Additionally, they are advancing hunTR, a platform focused on human neoantigen T-cell receptors, and mbIL-15, intended for solid tumor treatment. The company maintains strategic collaborations, including a licensing agreement with PGEN Therapeutics, Inc., a research and development partnership with The University of Texas MD Anderson Cancer Center, and both a patent licensing and R&D agreement with the National Cancer Institute. Previously known as ZIOPHARM Oncology, Inc., the company adopted its current name, Alaunos Therapeutics, Inc., in January 2022. Its headquarters are located in Houston, Texas.
URL
https://alaunos.com/
IPO date
Aug 20, 2004
Employees
34
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT